Great read on covid trials--treatments--MOA avi
Post# of 653
(Total Views: 377)
Posted On: 01/22/2022 11:28:43 PM
Great read on covid trials--treatments--MOA
aviptadil gets a shoutout on page 21 :
4.4. Aviptadil
Aviptadil (RLF-100, Zyesami, Figure 30) is the vasoactive intestinal peptide (VIP),
which binds specifically to the lung endothelium and reduces pulmonary inflammation by reducing the production of proinflammatory cytokines. NRx Pharmaceuticals has performed its clinical study in critical COVID-19 patients [63], finding good safety data, significative improvements in the levels of oxygenation and pulmonary function since the first days of treatment and a highly significant four-fold increased probability of survival.
Based on these results, in late December 2021, the company filed a breakthrough therapy designation request for aviptadil in patients at immediate risk of death from COVID-19 despite treatment with other approved therapies.
https://www.mdpi.com/1420-3049/27/3/658/htm
aviptadil gets a shoutout on page 21 :
4.4. Aviptadil
Aviptadil (RLF-100, Zyesami, Figure 30) is the vasoactive intestinal peptide (VIP),
which binds specifically to the lung endothelium and reduces pulmonary inflammation by reducing the production of proinflammatory cytokines. NRx Pharmaceuticals has performed its clinical study in critical COVID-19 patients [63], finding good safety data, significative improvements in the levels of oxygenation and pulmonary function since the first days of treatment and a highly significant four-fold increased probability of survival.
Based on these results, in late December 2021, the company filed a breakthrough therapy designation request for aviptadil in patients at immediate risk of death from COVID-19 despite treatment with other approved therapies.
https://www.mdpi.com/1420-3049/27/3/658/htm
(0)
(0)